Integra LifeSciences Holdings Corporation announced preliminary earnings results for the fourth quarter and full year 2016. For the quarter, the company expects its fourth quarter 2016 total revenue to be approximately $256 million. The company expects to report fourth-quarter 2016 organic revenue growth, which excludes the impact of foreign currency changes and revenue from discontinued and acquired products, of approximately 7.0%. The company expects fourth-quarter 2016 GAAP and adjusted diluted earnings per share to be at or above the mid-point of the prior guidance range of $0.32 to $0.35 and $0.50 to $0.53 post-stock split, respectively. For the year, the company expects its full-year 2016 revenue of approximately $992 million, at the low end of the previously provided guidance range. The company expects to report full-year 2016 organic growth of approximately 9.0%. This implies full-year 2016 GAAP and adjusted diluted earnings per share at or above the mid-point of the range of $0.91 to $0.94 and $1.73 to $1.77 post-stock split, respectively. At this point during the company's year-end close activities, the Company is not able to provide a breakdown of the components of the non-GAAP adjustments, but preliminarily estimates these to total $0.82 per share for the full year 2016. Operating cash flow, excluding approximately $43 million of accreted interest payment associated with the 2016 convertible notes that matured in December 2016, and free cash flow was strong. The company expects to be slightly above the high end of the previous guidance range for both metrics, above $145 million operating cash flow and above $105 million for free cash flow. The difference between operating cash flow and free cash flow is a preliminary estimate of $40 million for capital expenditures. The company is also provided preliminary 2017 revenue and adjusted earnings per share guidance for 2017. The company expects full-year 2017 organic revenue growth to be between 7% and 8.5%. This implies a revenue range of approximately $1.05 billion to $1.07 billion, inclusive of an unfavorable impact from foreign currency of approximately 1% at current exchange rates. Full-year 2017 earnings per share are expected to grow low double digits, exclusive of the unfavorable impact expected from foreign currency. The Company expects full-year 2017 adjusted earnings per share to be in the range of $1.91 to $1.97, taking into account a two cent negative impact from foreign currency. The Company is still in the process of reconciling estimates for full-year 2017 GAAP EPS projections and will provide this information and other additional information when full 2016 financial results are reported.